Professional Documents
Culture Documents
India Strategy - InCred - 28 Aug
India Strategy - InCred - 28 Aug
India
India Strategy
InCred Sector rating Great start to FY24 with EPS beat, upgrades
■ 1QFY24 results kick-started the Nifty-50 EPS beat trend and helped to drive
Overweight Neutral Underweight the EPS upgrade trend as well, after almost a year of weakness.
Aluminum Auto Ancillary Agribusiness
■ Strong market rally, especially in mid/small-caps, led to a poor risk-reward
Automobile Building Materials Aviation
ratio, and resulted in more stock rating downgrades in our coverage universe.
Cement Consumer staples Chemicals
Consumer Information
■ Large-caps relatively look attractive with the Nifty-50 index’s P/E valuation &
Electricals Technology
Diagnostics India P/E premium vs. Asia peers below the mean level. Retain Overweight.
Capital Goods Pharma Metals & Mining
Defense Ports & Logistics Sustained improvement in economic activity indicators
Financial The economic data points trend highlights sustained improvement in GST collection, strong
Services credit growth, goods movement (e-way bills), electricity consumption and kharif sowing. 1Q
Infrastructure GDP growth is likely to be strong at 8%, as per the Reserve Bank of India or RBI. However,
Oil and Gas the recent spike in Consumer Price Index or CPI inflation is an area of concern, but seems
transient as core CPI is still on a declining trend. The areas of concern are the weakness
in rainfall in recent weeks, lower corporate tax collection and slowdown in exports.
Sep'18
Dec'18
Sep'19
Dec'19
Sep'20
Dec'20
Sep'21
Dec'21
Sep'22
Dec'22
Mar'18
Mar'19
Mar'20
Mar'21
Mar'22
Mar'23
Jun'18
Jun'19
Jun'20
Jun'21
Jun'22
Jun'23
E pramod.amthe@incredcapital.com
Kashish THAKUR
T (91) 22 4161 1549 Nifty Earnings surprise (%)
E kashish.thakur@incredcapital.com
SOURCE: INCRED RESEARCH, COMPANY REPORTS
Powered by
EQUITEC
India
Strategy Note │ August 26, 2023
2
India
Strategy Note │ August 26, 2023
140
20.0
130
Rs tr
120
10.0
110
0.0 100
Nov-19
Nov-17
Nov-18
Nov-20
Nov-21
Nov-22
Mar-20
Mar-18
Mar-19
Mar-21
Mar-22
Mar-23
Jul-17
Jul-18
Jul-19
Jul-20
Jul-21
Jul-22
Jul-23
90
Dec-20
Aug-19
Dec-19
Aug-20
Aug-21
Dec-21
Aug-22
Dec-22
Apr-21
Oct-19
Apr-20
Oct-20
Oct-21
Apr-22
Oct-22
Apr-23
Feb-21
Jun-19
Feb-20
Jun-20
Jun-21
Feb-22
Jun-22
Feb-23
Jun-23
-10.0
Non-food Agriculture and allied activities
Industry Personal loans
Services Non-food credit…
Figure 5: Car sales registrations on the growth path while the weakness in electric
vehicles or EVs and two-wheelers in recent months disappoint
4,50,000 20,00,000
4,00,000 18,00,000
3,50,000 16,00,000
14,00,000
3,00,000
(units)
(units)
12,00,000
2,50,000
10,00,000
2,00,000
8,00,000
1,50,000
6,00,000
1,00,000 4,00,000
50,000 2,00,000
0 0
Oct-19
Apr-20
Oct-20
Apr-21
Oct-21
Apr-22
Oct-22
Apr-23
Jul-21
Jul-19
Jan-20
Jul-20
Jan-21
Jan-22
Jul-22
Jan-23
Jul-23
3
India
Strategy Note │ August 26, 2023
5,000
4,500
4,000
MU
3,500
3,000
2,500
2,000
Dec-20
Aug-19
Dec-19
Aug-20
Aug-21
Dec-21
Aug-22
Dec-22
Aug-23
Oct-19
Apr-20
Oct-20
Apr-21
Oct-21
Apr-22
Oct-22
Apr-23
Feb-20
Jun-20
Feb-21
Jun-21
Feb-22
Jun-22
Feb-23
Jun-23
Average Monthly Electricity Generation (MU)
2,000
1,800
1,600
1,400
Rs bn
1,200
1,000
800
600
400
200
0
Jul-19
Jul-20
Jul-21
Jul-22
Jul-23
Oct-19
Oct-20
Oct-21
Oct-22
Jan-19
Jan-20
Jan-21
Jan-22
Jan-23
Apr-19
Apr-20
Apr-21
Apr-22
Apr-23
GST collection (Rs bn)
NOTE: GST IS GOODS AND SERVICES TAX
SOURCE: GST COUNCIL, INCRED RESEARCH
1.0 0.8
0.5 0.3
0.0
Nov-19
Dec-19
Nov-20
Dec-20
Nov-21
Dec-21
Nov-22
Dec-22
May-19
May-20
May-21
May-22
May-23
Apr-21
Apr-19
Aug-19
Sep-19
Oct-19
Apr-20
Aug-20
Sep-20
Oct-20
Aug-21
Sep-21
Oct-21
Apr-22
Aug-22
Sep-22
Oct-22
Apr-23
Mar-22
Feb-23
Feb-20
Mar-20
Feb-21
Mar-21
Feb-22
Mar-23
Jun-19
Jul-19
Jan-20
Jun-20
Jul-20
Jan-21
Jun'21
Jul-21
Jan-22
Jun-22
Jul-22
Jan-23
Jun-23
Jul-23
4
India
Strategy Note │ August 26, 2023
2500000
2000000
1500000
1000000
500000
5
India
Strategy Note │ August 26, 2023
Figure 10: The improvement in Consumer Sentiment Index from its Jul 2023 low
provides comfort
100
96
92
88
84
Absolute value
80
76
72
68
64
60
56
52
48
44
40
36
30-Apr-21
01-Apr-22
25-Apr-22
20-Apr-23
15-Oct-21
10-Oct-22
17-Jun-21
19-Jan-22
12-Feb-22
08-Mar-22
12-Jun-22
14-Jan-23
07-Feb-23
03-Mar-23
27-Mar-23
07-Jun-23
08-Nov-21
02-Dec-21
26-Dec-21
11-Jul-21
06-Jul-22
30-Jul-22
01-Jul-23
25-Jul-23
24-May-21
04-Aug-21
28-Aug-21
21-Sep-21
19-May-22
23-Aug-22
16-Sep-22
03-Nov-22
27-Nov-22
21-Dec-22
14-May-23
18-Aug-23
All-India Urban Rural
Figure 11: This year’s rainfall deviation from the last five years’ average
150%
Regionwise Departure from Long Period
100%
50%
Average
0%
-50%
-100%
East & North North West Central India South Peninsula India
East India India
SOURCE: IMD, THE CENTRE FOR MONITORING INDIAN ECONOMY OR CMIE, INCRED RESEARCH
Figure 12: Consumer perception touches a new high while Figure 13: Consumer perception on non-essential spending
spending perception keeps on declining improves sharply while the expectation marginally eases from
May 2023 level
88 15
86 10
84 5
0
82
-5
80
-10
78
-15
76
-20
74 -25
72 -30
70 -35
May-22 Jul-22 Sep-22 Nov-22 Jan-23 Mar-23 May-23 Jul-23 May-22 Jul-22 Sep-22 Nov-22 Jan-23 Mar-23 May-23 Jul-23
SOURCE: CMIE, INCRED RESEARCH, RBI. SOURCE: CMIE, INCRED RESEARCH, RBI.
6
India
Strategy Note │ August 26, 2023
3,500
3,000
2,500
2,000
1,500
1,000
500
Sep-20
Nov-20
May-21
Sep-21
Nov-21
May-22
Sep-22
Nov-22
May-23
Jan-21
Mar-21
Jan-22
Mar-22
Jul-22
Jan-23
Mar-23
Jul-20
Jul-21
Jul-23
Naukri Jobspeak Hiring Index
Figure 15: Hiring Intent Index of Team Lease – Tier-1&3 cities ease from their peak
levels
100%
90%
80%
70%
60%
Hiring Intent (%)
50%
40%
30%
20%
10%
0%
1QFY22
4QFY23
4QFY21
2QFY22
3QFY22
4QFY22
1QFY23
2QFY23
3QFY23
1QFY24
1HFY20
2HFY20
1HFY21
7
India
Strategy Note │ August 26, 2023
Figure 16: Index of Industrial Production growth is steady Figure 17: India PMI (updated till data available)
10.0 60
5.0
55
0.0
-5.0 50
-10.0
45
-15.0
-20.0 40
Dec-22
Dec-19
Aug-20
Dec-20
Dec-21
Aug-19
Oct-19
Apr-20
Oct-20
Apr-21
Aug-21
Oct-21
Apr-22
Aug-22
Oct-22
Apr-23
Jun-21
Feb-22
Jun-19
Feb-20
Jun-20
Feb-21
Jun-22
Feb-23
Jun-23
Oct-21
Dec-19
Dec-20
Dec-21
Dec-22
Aug-19
Oct-19
Apr-20
Aug-20
Oct-20
Apr-21
Aug-21
Apr-22
Aug-22
Oct-22
Apr-23
Feb-23
Feb-20
Feb-21
Feb-22
Jun-22
Jun-19
Jun-20
Jun-21
Jun-23
IIP growth % yoy
Figure 18: Bloomberg’s India GDP consensus growth estimate on the rise
FY24F FY25F
6.6
6.5
6.4 6.4
6.3
6.2
6.1 6.1
6
5.9
5.8
5.7
8
India
Strategy Note │ August 26, 2023
50 5
45 0
35
30 -10
25 -15
20 -20
15
-25
10
5 -30
0 -35
Nov-16
Nov-17
Nov-18
Nov-19
Nov-20
Nov-21
Nov-22
Mar-17
Mar-18
Mar-19
Mar-20
Mar-21
Mar-22
Mar-23
Jul-23
Jul-16
Jul-17
Jul-18
Jul-19
Jul-20
Jul-21
Jul-22
Exports USD Bn Trade Balance USD Bn
Figure 20: INR’s performance vs. Asian peers over the last one year (against USD)
4% 3%
3%
2% 2%
1%
0%
-1%
-1%
-2%
-2% -2% -2%
-3%
-3%
-4%
-4%
-5%
Indian Chinese Japanese South Taiwanese Indonesian Malaysian Thai Baht
Rupee Renminbi Yen Korean Dollar Rupiah Ringgit
Won
9
Probability of recession (%)
India
-6.5
-5.5
-5
-4.5
-7
-6
38000
40000
42000
46000
48000
50000
52000
44000
Aug-22
0
10
20
30
40
50
60
70
80
90
100
Sep-22 21-Aug-22
Aug-22
05-Sep-22 US
Sep-22 Sep-22
remains stable.
Oct-22 20-Sep-22
Sep-22
Oct-22 05-Oct-22
Oct-22
20-Oct-22
10
Nov-22 Oct-22
Nov-22 04-Nov-22 Nov-22
Eurozone
Dec-22 19-Nov-22
Strategy Note │ August 26, 2023
Nov-22
Dec-22 04-Dec-22 Dec-22
Jan-23 19-Dec-22 Dec-22
UK
FY24F
Feb-23 02-Feb-23 Feb-23
Mar-23 17-Feb-23 Feb-23
Mar-23 04-Mar-23 Mar-23
Germany
FY25F
Apr-23 03-Apr-23 Apr-23
May-23
Total Forex Reserves (Rs bn)
18-Apr-23 Apr-23
May-23 03-May-23 May-23
Figure 22: Total forex reserves (US$ bn) continue their uptrend
Jun-23 May-23
18-May-23
France
Jun-23 Jun-23
02-Jun-23
Jul-23 Jun-23
17-Jun-23
Jul-23 Jul-23
02-Jul-23
Aug-23 Jul-23
17-Jul-23
Aug-23 Aug-23
01-Aug-23
Figure 23: Bloomberg consensus estimates on GoI’s fiscal deficit (as a % of GDP)
5.9
Aug-23
5.25
16-Aug-23
Figure 21: Consensus estimates on probability of a recession in developed countries
Jul-20
Jul-21
Jul-23
Jan-20
Oct-20
Jan-21
Jan-22
Jan-23
Oct-19
Oct-21
Oct-22
Apr-19
Apr-20
Apr-21
Apr-22
Apr-23
May-20
May-21
May-22
May-23
Sep-19
Nov-19
Mar-20
Sep-20
Nov-20
Mar-21
Sep-21
Nov-21
Mar-22
Sep-22
Nov-22
Mar-23
Jan-20
Jul-19
Jul-20
Jan-21
Jul-21
Jan-22
Jul-22
Jan-23
Jul-23
11
India
Strategy Note │ August 26, 2023
Figure 26: Bloomberg CPI inflation consensus estimates Figure 27: Bloomberg consensus estimates on WPI inflation
6.5 10
6 8
5.5 6
5.2
5 4 4.0
4.8
4.5 2
0.6
4 0
May-22
May-22
May-23
Oct-22
Apr-23
Apr-22
Oct-22
Apr-23
Aug-23
Aug-23
Apr-22
Aug-22
Sep-22
Oct-22
Oct-22
Nov-22
Dec-22
Apr-23
May-22
May-22
Aug-22
Aug-22
Sep-22
Nov-22
Dec-22
Dec-22
May-23
Feb-22
Mar-22
Jan-23
Feb-23
Mar-23
Mar-23
Mar-22
Jun-22
Jan-23
Jan-22
Jan-22
Jun-22
Jul-22
Jun-23
Jul-23
Jul-23
Jan-22
Jan-22
Feb-22
Mar-22
Jun-22
Feb-23
Feb-23
Mar-23
Jun-23
Jun-23
Jul-22
Jul-23
NOTE: CPI ISCONSUMER PRICE INDEX NOTE: WPI IS WHOLESALE PRICE INDEX
SOURCE: BLOOMBERG, INCRED RESEARCH SOURCE: BLOOMBERG, INCRED RESEARCH
Figure 28: Bloomberg consensus estimate expects the repo rate to be cut by 75bp in
the next one year
6.9%
6.8%
6.7%
6.6%
6.5%
Repo rate
6.4%
6.3%
6.2%
6.1%
6.0%
5.9%
5.8%
5.7%
2QFY24F
3QFY24F
4QFY24F
1QFY25F
2QFY25F
3QFY25F
4QFY25F
1QFY26F
2QFY26F
3QFY26F
Bloomberg consensus weighted average estimate for India's repo rate (%)
SOURCE: BLOOMBERG, INCRED RESEARCH
Figure 29: Weighted average lending rate of banks begins to ease Figure 30: Weighted average lending rate of banks stabilize
from their peak (fresh INR loans) (outstanding rupee loans)
10.5 10.5
10 10
9.5 9.5
9 9
8.5 8.5
8 8
7.5 7.5
7 7
6.5 6.5
6 6
May-20
May-21
May-22
May-23
Nov-19
May-20
Nov-20
May-21
Nov-21
May-22
Nov-22
May-23
Sep-19
Sep-20
Sep-21
Sep-22
Sep-19
Nov-19
Sep-20
Nov-20
Sep-21
Nov-21
Sep-22
Nov-22
Mar-20
Mar-21
Mar-22
Mar-23
Jul-19
Jan-20
Jul-20
Jan-21
Jul-21
Jan-22
Jul-22
Jan-23
Jul-23
Mar-20
Mar-21
Mar-22
Mar-23
Jul-19
Jan-20
Jul-20
Jan-21
Jul-21
Jan-22
Jul-22
Jan-23
Jul-23
All SCB Public Sector Banks All SCB Public Sector Banks
12
India
Strategy Note │ August 26, 2023
Investment themes
We continue to like our housing and infrastructure capex investment themes
as a top-down approach, with order book surge and sales momentum
improvement in 1QFY24. Considering the rich valuation challenge in mid-
caps, we have changed our stock picks from the segment.
25000 30%
25%
20000
20%
15000
15%
10000
10%
5000
5%
0 0%
13
India
Strategy Note │ August 26, 2023
Figure 32: Housing sales trend for eight prime housing markets in India saw a slight dip
QoQ
1,00,000 10,00,000
90,000 9,00,000
80,000 8,00,000
70,000 7,00,000
60,000 6,00,000
50,000 5,00,000
40,000 4,00,000
30,000 3,00,000
20,000 2,00,000
10,000 1,00,000
0 -
2QFY20
3QFY20
4QFY20
1QFY21
2QFY21
3QFY21
4QFY21
1QFY22
2QFY22
3QFY22
4QFY22
1QFY23
2QFY23
3QFY23
4QFY23
1QFY24
Housing Sales (units) Unsold Inventory (units) (RHS)
Figure 33: Housing sales data for top eight cities in India saw a 36% rise YoY, and the
rise was led by higher sales in Pune
40,000
35,000
30,000
25,000
units
20,000
15,000
10,000
5,000
0
4QFY20
1QFY21
2QFY21
3QFY21
4QFY21
1QFY22
2QFY22
3QFY22
4QFY22
1QFY23
2QFY23
3QFY23
4QFY23
1QFY24
NCR MMR Bengaluru Pune Hyderabad Chennai Kolkata
SOURCE: ANAROCK, INCRED RESEARCH
14
India
Strategy Note │ August 26, 2023
The aggregate order inflow was robust, up 46% YoY, for our capital
goods/infrastructure coverage universe, led by a 56% YoY growth in Larsen &
Toubro or L&T. All the companies under our coverage universe reported a higher
order inflow YoY. New investments announced during 1HCY23 grew 28% YoY.
We expect a new trend of private sector spending led by the energy sector’s
transition including renewables, electric vehicles, battery technology, and
hydrogen. We expect manufacturing capex led by production-linked incentive or
PLI schemes, supply chain diversification and the China+ strategy.
Figure 35: Central government’s capital expenditure to sustain its 32% CAGR over
FY21-24BE
12
10.0
10
8 7.3
5.9
6
4.3
Rs tr
4 3.1 3.4
2.5 2.8 2.6
2.0
2 1.6 1.6 1.7 1.9
1.1 1.2 0.9 1.1
0.7 0.7
0
FY05
FY06
FY07
FY08
FY09
FY10
FY11
FY12
FY13
FY14
FY15
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY24
Central capital expenditure trend
SOURCE: CMIE, INCRED RESEARCH
Figure 36: Improvement in capacity utilization (CU) and de-trended IIP (manufacturing)
15
India
Strategy Note │ August 26, 2023
1.5
0.5
Jan-09
Jul-08
Jan-10
Jan-11
Jan-12
Jan-13
Jan-14
Jan-15
Jan-16
Jan-17
Jan-18
Jan-19
Jan-20
Jan-21
Jan-22
Jan-23
Jul-09
Jul-10
Jul-11
Jul-12
Jul-13
Jul-14
Jul-15
Jul-16
Jul-17
Jul-18
Jul-19
Jul-20
Jul-21
Jul-22
Jul-23
Upgrade/Downgrade Ratio (RHS)
16
India
Strategy Note │ August 26, 2023
Figure 39: High-conviction stocks’ price performance since their introduction on 10 Sep 2022
12%
7.3%
8%
4.6% 4.7%
3.1% 2.6%
4% 1.9% 2.1% 2.0% 1.7%
0.7% 0.6% 1.1% 1.1% 0.9% 0.4% 0.7%
0.0%
0%
0.0%
-1.2%
-4% -2.9%
-4.8%
-8%
-12%
Indigo
BCL Industries
Concor
Reliance Industry
Nifty 200
Dalmia Bharat
Globus Spirits
Torrent Pharma
Nifty 50
Bharat Electronics
Bharat Forge
HDFC Bank
Maruti Suzuki
Tata Steel
M&M Financial Services
Spandana Sphoorty
Ultratech Cement
Clean Science
Ashok Leyland
NOTE: PERFORMANCE IS BASED ON COMPOUNDED MONTHLY GROWTH RATE, FROM THE DAY THE STOCK WAS ADDED TO THE PORTFOLIO
SOURCE: BLOOMBERG, INCRED RESEARCH
Figure 40: High-conviction stocks’ price absolute performance since their introduction on 10 Sep 2022
40% 9/22
5/23
30% 9/22
9/23
12/22 12/22
20% 6/23 9/22 3/23 6/23
9/22 9/22 12/22 9/22
2/23 9/22
10%
8/23 8/23 7/23
12/22
0%
9/22
-10%
7/23
-20% 9/22
-30%
9/22
-40%
Spandana Sphoorty
BCL Industries
Torrent Pharma
Indigo
Camlin Fine
Concor
Reliance Industry
Nifty 200
Dalmia Bharat
Globus Spirits
Sun Pharma
Nifty 50
Bharat Electronics
Bharat Forge
Maruti Suzuki
Tata Steel
Ultratech Cement
HDFC Bank
KEI International
Thermax
Ashok Leyland
17
India
Strategy Note │ August 26, 2023
15% 13% Rs
20%
13% 250 70%
8%
10% 4% 5% 3% 4%
1% 1% 2% 60%
0% 200 50%
-1% -2% -1%
-10% -4%-2% -2% 40%
-10%
-20% 150 30%
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Jun'23
Jun'18
Sep'18
Jun'19
Sep'19
Jun'20
Sep'20
Jun'21
Sep'21
Jun'22
Sep'22
Mar'20
Mar'21
Mar'18
Mar'19
Mar'22
Mar'23
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Jun'22
Jun'17
Jun'18
Jun'19
Jun'20
Jun'21
Jun'23
Nifty Earnings surprise (%) Nifty EPS (Rs) YoY growth (%)
18
100%
0%
10%
20%
30%
50%
70%
80%
90%
40%
60%
-60%
-40%
-20%
100%
0%
20%
40%
80%
60%
4QFY18
Agri
1QFY19
2QFY19 Alcohol
3QFY19
4QFY19 Automobile & Ancillaries
1QFY20 Bank
2QFY20
3QFY20 Capital Goods
Positive
4QFY20
Chemicals
1QFY21
2QFY21 Construction Materials
In line
3QFY21
4QFY21 Consumer Durables
1QFY22 Crude Oil
2QFY22
Negative
3QFY22 Electricals
Figure 43: BSE-500 sector-wise EBITDA growth
India
4QFY22 Finance
Rs
0
1,000
1,200
1,400
200
400
600
800
1QFY23
Jun-14 2QFY23 FMCG
Sep-14 3QFY23
Dec-14 Gas Transmission
Mar-15 4QFY23
Jun-15 1QFY24 Healthcare
Sep-15
19
Mar-16
Jun-16 Inds. Gases & Fuels
Sep-16
100%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Strategy Note │ August 26, 2023
Dec-16 Infrastructure
EBITDA growth yoy
Mar-17
Jun-17 4QFY18 Insurance
Sep-17 1QFY19
Dec-17 2QFY19 Iron & Steel
Revenue (Rs)
Mar-18 3QFY19
Jun-18 IT
Sep-18 4QFY19
Dec-18 1QFY20 Logistics
Mar-19 2QFY20
Jun-19 Media & Entertainment
3QFY20
Positive
Sep-19
Dec-19 4QFY20 Mining
Mar-20 1QFY21
Jun-20 2QFY21 Miscellaneous
In line
Sep-20 3QFY21
Dec-20 Non - Ferrous Metals
Mar-21 4QFY21
Jun-21 1QFY22 Plastic Products
Dec-21 Power
3QFY22
Mar-22
Jun-22 4QFY22 Realty
Sep-22 1QFY23
Textile
0%
1QFY24
10%
20%
30%
40%
-30%
-20%
-10%
Figure 47: Bloomberg Industrial Metal Index and Commodity Index ease
240
220
200
180
160
140
120
100
80
60
40
Aug-19
Sep-19
Aug-20
Sep-20
Aug-21
Sep-21
Aug-22
Sep-22
Aug-23
Dec-19
Dec-22
Oct-20
Nov-19
May-20
Nov-20
Dec-20
May-21
Nov-21
Dec-21
May-22
Nov-22
May-23
Oct-19
Apr-20
Apr-21
Oct-21
Apr-22
Oct-22
Apr-23
Jan-20
Feb-20
Mar-20
Jun-20
Jan-21
Feb-21
Mar-21
Jun-21
Jan-22
Feb-22
Mar-22
Jun-22
Jan-23
Feb-23
Mar-23
Jun-23
Jul-20
Jul-21
Jul-22
Jul-23
Bloomberg Industrial Metal Index Bloomberg Commodity Index
Figure 48: Global Commodity Index trend correction continues, except in case of the
energy sector
200
180
160
Index 2010=100
140
120
100
80
60
40
20
0
Oct-19
Apr-20
Oct-13
Apr-14
Oct-14
Apr-15
Oct-15
Apr-16
Oct-16
Apr-17
Oct-17
Apr-18
Oct-18
Apr-19
Oct-20
Apr-21
Oct-21
Apr-22
Oct-22
Apr-23
Jan-14
Jan-15
Jan-16
Jan-17
Jan-18
Jan-19
Jan-20
Jan-21
Jan-22
Jan-23
Jul-13
Jul-14
Jul-15
Jul-16
Jul-17
Jul-18
Jul-19
Jul-20
Jul-21
Jul-22
Jul-23
Energy Non-Energy Food Metals & Minerals
Nifty Index F12 Est. Nifty Index F12+1 Est. Nifty Index F12+2 Est.
1400
1300
1200
1100
1000
900
800
February March April May June July August
20
India
Strategy Note │ August 26, 2023
Figure 50: Nifty-200 EPS upgrade driven by automobile, oil marketing and pharmaceutical companies (from 1 Jul 2023)
%
FY24F Major EPS Up/Dowgrade from Nifty 200 (Since July'23)
100%
80%
60% 51%
DeepakNitrite
DalmiaBharat
HPCL
Indigo
FSN
TechM
UPL
AshokLeyland
Lupin
One97
LICHousing
PBFintech
AdityaBirlaFash
TataMotors
LIC
LaurusLabs
Escorts
Piramal enterprices
Biocon
ZydusLife
Zomato
Delhivery
Poonawalla
BPCL
AdaniWilmar
Figure 51: Recent Bloomberg consensus EPS trend change for Nifty-50 and Nifty-200
companies
Nifty-50 EPS Nifty-200 EPS
FY24F FY25F FY24F FY25F
15 days 1.18% 1.13% 15 days 0.86% 0.90%
30 days 1.06% 2.23% 30 days 1.37% 2.14%
60 days 1.33% 3.05% 60 days 1.90% 2.97%
120 days 0.23% 2.46% 120 days 1.67% 2.78%
SOURCE: BLOOMBERG, INCRED RESEARCH
21
India
Strategy Note │ August 26, 2023
Aug-14
Aug-15
Aug-16
Aug-17
Aug-18
Aug-19
Aug-20
Aug-21
Aug-22
Aug-23
Feb-14
Feb-15
Feb-16
Feb-17
Feb-18
Feb-19
Feb-20
Feb-21
Feb-22
Feb-23
Nifty 1-year forward P/E 10-year mean -1 s.d +1 s.d. -2 s.d +2 s.d.
22
India
Strategy Note │ August 26, 2023
Figure 53: Real earnings yield for Nifty-50 companies in an uncomfortable zone
15%
10%
5%
0%
-5%
-10%
Aug-22
Aug-08
Aug-09
Aug-10
Aug-11
Aug-12
Aug-13
Aug-14
Aug-15
Aug-16
Aug-17
Aug-18
Aug-19
Aug-20
Aug-21
Aug-23
Feb-20
Feb-09
Feb-10
Feb-11
Feb-12
Feb-13
Feb-14
Feb-15
Feb-16
Feb-17
Feb-18
Feb-19
Feb-21
Feb-22
Feb-23
SOURCE: BLOOMBERG, INCRED RESEARCH
Figure 54: Market-cap distribution of stocks in top-500 stocks indicate excess fizz in
the mid-cap rally, as stocks in the basket of beyond 250 by market-cap list scale a new-
high proportion at 10.2% of total market cap
20%
18%
16%
14%
12%
10%
8%
6%
4%
2%
0%
August, 2006
August, 1999
August, 2000
August, 2001
August, 2002
August, 2003
August, 2004
August, 2005
August, 2007
August, 2008
August, 2009
August, 2010
August, 2011
August, 2012
August, 2013
August, 2014
August, 2015
August, 2016
August, 2017
August, 2018
August, 2019
August, 2020
August, 2021
August, 2022
SOURCE: BLOOMBERG, INCRED RESEARCH
August, 2023
23
0
2
6
8
-8
-6
-4
-2
10
100
300
400
500
600
700
800
200
900
0
Jul-18
Sep-18 Jul-18
Nov-18 Sep-18
Jan-19 Nov-18
Mar-19 Jan-19
May-19 Mar-19
Jul-19 May-19
Sep-19 Jul-19
Nov-19 Sep-19
Jan-20 Nov-19
Mar-20 Jan-20
May-20 Mar-20
Jul-20 May-20
Sep-20 Jul-20
Nov-20 Sep-20
Jan-21 Nov-20
Mar-21 Jan-21
May-22 Mar-22
May-23
Jul-23 May-23
SOURCE: BLOOMBERG, INCRED RESEARCH Jul-23
24
-8
-6
-4
-2
0
2
4
6
8
10
12
-10
-150
-100
0
-50
50
100
150
200
250
300
350
Strategy Note │ August 26, 2023
Jul-18
Sep-18 Jul-19
Nov-18 Sep-19
Jan-19 Nov-19
Mar-19 Jan-20
May-19
Jul-19 Mar-20
Sep-19 May-20
Nov-19 Jul-20
Jan-20 Sep-20
Mar-20 Nov-20
May-20
Jul-20 Jan-21
Sep-20 Mar-21
Nov-20 May-21
Jan-21 Jul-21
Mar-21
May-21 Sep-21
Jul-21 Nov-21
Sep-21 Jan-22
Jul-22
Figure 59: FII inflows build the growth momentum
May-22
Figure 57: Domestic mutual fund inflows inching up
Jul-22 Sep-22
Sep-22 Nov-22
Nov-22 Jan-23
Jan-23
Mar-23 Mar-23
May-23 May-23
Jul-23 Jul-23
SOURCE: BLOOMBERG, INCRED RESEARCH
SOURCE: BLOOMBERG, INCRED RESEARCH
India
Strategy Note │ August 26, 2023
50%
45% 43%
40% 38%
35%
30% 27% 28%
26%
25%
20%
20% 16%
15% 12% 13%
10% 8% 8%
5%
0%
Nifty 50 Nifty Nifty IT Nifty BSE Nifty Nifty Nifty Nifty Nifty Nifty
Auto FMCG Capital Bank Pharma Realty Metal Energy Defence
Goods
25
India
Strategy Note │ August 26, 2023
Figure 62: Nifty mid-cap and Nifty small-cap indices outperform Nifty-50 from Apr 2023
128
123
118
113
108
103
98
93
88
01-01-2023
08-01-2023
15-01-2023
22-01-2023
29-01-2023
05-02-2023
12-02-2023
19-02-2023
26-02-2023
05-03-2023
12-03-2023
19-03-2023
26-03-2023
02-04-2023
09-04-2023
16-04-2023
23-04-2023
30-04-2023
07-05-2023
14-05-2023
21-05-2023
28-05-2023
04-06-2023
11-06-2023
18-06-2023
25-06-2023
02-07-2023
09-07-2023
16-07-2023
23-07-2023
30-07-2023
06-08-2023
13-08-2023
20-08-2023
SOURCE: INCRED RESEARCH, BLOOMBERG
Figure 63: Non-consensus stocks with a REDUCE rating in our coverage universe
Bloomberg Target Market Market EV/EBITDA Dividend Upside/ ROE
Company Name Reco Price EPS (Rs) P/E (x) P/BV (x)
Ticker Price Capital Capital (x) Yield (%) Downside (%)
Rs Rs (Rs bn) (US$ bn) FY24F FY25F FY24F FY25F FY24F FY25F FY24F FY24F (%) FY24F
Apollo Tyres APTY IN REDUCE 393 343 249 3 23.4 24.6 16.8 16.0 1.9 1.8 6.5 1.8 -13% 11.1
Avanti Feeds AVNT IN REDUCE 422 353 57 1 22.1 NA 19.1 NA 2.8 2.5 11.2 1.0 -16% 13.8
Balrampur Chini Mills BRCM IN REDUCE 391 229 79 1 24.9 22.9 15.7 17.1 2.6 2.3 10.7 0.3 -41% 21.3
Bharat Petroleum BPCL IN REDUCE 345 375 747 9 38.1 NA 9.0 NA 1.5 1.4 7.3 5.7 9% 16.3
Clean Science and
CLEAN IN REDUCE 1,404 660 149 2 29.4 33.8 47.8 41.6 15.6 12.9 36.5 - -53% 29.5
Technology
Dhanuka Agritech DAGRI IN REDUCE 789 704 36 0.4 48.2 NA 16.4 NA 3.4 2.9 (0.8) 1.2 -11% 19.0
Eicher Motors EIM IN REDUCE 3,358 3,053 918 11.1 132.4 145.4 25.4 23.1 7.0 5.9 18.8 1.3 -9% 25.3
Finolex Industries FNXP IN REDUCE 216 177 134 1.6 7.6 9.8 15.8 22.0 2.7 2.4 16.5 1.9 -18% 14.1
Galaxy Surfactants GALSURF IN REDUCE 2,700 2,552 96 1.2 84.7 90.4 31.9 29.9 4.9 4.3 19.4 0.1 -5% 14.4
Hero MotoCorp HMCL IN REDUCE 2,952 2,419 589 7.1 194.9 221.2 15.1 13.3 3.5 3.3 9.3 4.4 -18% 22.5
InterGlobe Aviation INDIGO IN REDUCE 2,497 1,600 962 11.7 (16.0) (9.3) (156.2) (269.3) (11.0) (10.3) 17.3 - -36% 9.1
NCC NJCC IN REDUCE 154 104 96 1.2 12.2 12.7 12.6 12.1 1.6 1.4 8.0 0.4 -32% 15.7
SRF SRF IN REDUCE 2,311 1,540 684 8 54.2 63.4 42.6 36.5 6.6 5.8 24.9 0.3 -33% 14.6
Tata Motors TTMT IN REDUCE 614 401 2,241 27.1 20.2 39.4 30.5 15.6 5.2 4.6 5.7 0.7 -35% 15.9
Tata Steel TATA IN REDUCE 119 70 1,452 17.6 5.3 NA 22.6 NA 1.2 1.1 8.4 1.7 -41% 5.1
Triveni Engineering and
TRE IN REDUCE 306 191 67 0.8 18.1 19.2 16.9 16.0 2.0 2.1 12.3 0.3 -38% 16.5
Industries
VRL Logistics VRLL IN REDUCE 686 426 60 1 11.3 14.4 60.8 47.6 6.9 6.5 17.2 0.7 -38% 10.9
SOURCE: INCRED RESEARCH ESTIMATES, BLOOMBERG, COMPANY REPORTS
NOTE: PRICES AS ON 24TH AUG 2023
Figure 64: Figure 65: Our key mid-cap and small-cap stock recommendations
EV/ Dividen
Bloomberg Target Market Market Upside/ ROE
Company Name Reco. Price EPS (Rs) P/E (x) P/BV (x) EBITDA d Yield
Ticker Price Capital Capital Downside (%)
(x) (%)
(US$ FY24 FY25 FY24
Rs Rs (Rs bn) FY24F FY25F FY24F FY25F FY24F FY24F (%)
bn) F F F
Ajanta Pharma AJP IN ADD 1,767 1,729 222 2.7 60.6 69.3 29.2 25.5 6.7 5.5 20.2 0.4 -2% 20.8
Apex Frozen Foods APEX IN ADD 220 385 7 0.1 25.7 NA 8.6 NA 1.3 1.2 5.5 1.2 75% 19.6
Balkrishna Industries BIL IN REDUCE 2,380 1,790 459 5.6 65.9 80.3 36.1 29.7 6.1 5.5 21.4 0.9 -25% 15.9
Coastal Corp CTW IN ADD 298 990 4 0.0 55.3 99.0 5.4 3.0 1.5 1.2 4.7 3.3 233% 34.0
Cyient CYL IN ADD 1,547 1,681 171 2.1 66.0 76.0 23.4 20.4 4.9 4.5 13.1 2.3 9% 26.9
Endurance
ENDU IN ADD 1,626 1,647 228 2.8 50.3 62.9 32.3 25.8 5.2 4.6 17.1 0.6 1% 15.1
Technologies
Globus Spirits GBSL IN ADD 944 3,014 27 0.3 120.6 140.5 7.8 6.7 3.0 2.2 5.3 0.8 219% 32.8
Gujarat Pipavav Port GPPV IN ADD 118 148 57 0.7 8.3 10.1 14.2 11.6 2.7 2.6 7.2 5.3 26% 18.7
HEG HEG IN ADD 1,783 2,462 69 0.8 108.2 171.7 16.5 10.4 1.6 1.4 9.6 1.7 38% 9.0
Home First Finance
HOMEFIRS IN ADD 864 1,050 76 0.9 32.8 39.0 26.3 22.2 4.2 3.6 NA NA 22% 14.7
Company
KEC International KECI IN ADD 649 725 167 2.0 22.8 36.1 28.4 18.0 4.4 3.9 13.8 0.8 12% 14.7
Metropolis Healthcare METROHL IN ADD 1,325 1,553 68 0.8 32.2 39.7 41.1 33.4 6.9 6.2 20.4 0.8 17% 15.8
Meghmani Finechem MEGHFL IN ADD 888 2,151 37 0.4 107.5 NA 8.3 NA 2.8 2.1 6.0 - 142% 34.1
PI Industries PI IN REDUCE 3,691 2,417 559 6.8 85.2 96.7 43.3 38.2 7.7 6.5 28.8 0.1 -35% 16.3
Supreme Industries SI IN ADD 4,433 3,949 562 6.8 82.6 98.7 53.7 44.9 12.8 11.1 38.2 0.6 -11% 27.9
Som Distilleries &
SDB IN ADD 325 393 25 0 10.6 13.5 30.7 24.0 6.4 4.6 18.4 0.3 21% 22.8
Breweries
Zydus Lifesciences ZYDUSLIF IN REDUCE 645 585 652 8 31.4 33.4 20.6 19.3 3.7 3.3 14.2 1.1 -9% 16.9
SOURCE: INCRED RESEARCH ESTIMATES, BLOOMBERG, COMPANY REPORTS
NOTE: PRICES AS ON 24TH AUG 2023
26
India
Strategy Note │ August 26, 2023
Automobile sector
• A good 1QFY24 results season was witnessed in our coverage universe
stocks, as 88% of the stocks beat on the EBITDA front. The big beat was in
commercial vehicle or CV and tractor original equipment manufacturers or
OEMs. 2W OEMs marginally disappointed. Companies with international
exposure were impressive, except for Balkrishna Industries.
• Among OEMs, gross margin qoq improvement was seen except in the case of
two-wheeler or 2W makers. In the auto component segment, there was margin
erosion, except in the case of tyre-makers who were aided by lower input cost.
• Management commentaries on commodity cost outlook have been mixed this
time, with most of them stating that lower costs are reflected in the quarter’s
profitability while a marginal rise in cost from the lower level is seen now. The
strong ASP improvement across OEMs helped raise sales, despite volume cut
by many. The major EBITDA upgrade in our coverage universe was for Escorts
Kubota, Mahindra & Mahindra, Ashok Leyland and Bajaj Auto among OEMs.
In the auto component space, major upgrade was in the case of Apollo Tyres,
SAMIL and Bharat Forge. Only Balkrishna Industries in our coverage universe
witnessed an EBITDA cut. The higher other income trend helped amplify EPS
upgrade across our coverage universe.
• We reiterate Overweight rating on the automobile sector, as NSE Auto Index
valuation is near the 10-year mean level and EBITDA surprises flow in. We
maintain pre-results rating upgrade of SAMIL to ADD. The festive season-led
demand recovery provides hope for two-wheeler sales, where we prefer Bajaj
Auto. Maruti Suzuki, with strong new products and alternative fuel technology,
is better positioned to gain market share in the car segment. We have an ADD
rating on Mahindra & Mahindra and Ashok Leyland as these segment leaders
are gaining market share through new product launches. Our order of
preference is Bajaj Auto, Ashok Leyland, Mahindra & Mahindra and Maruti
Suzuki. The corporate governance concerns in large-cap OEMs like Hero
MotoCorp (government inquiry), Mahindra & Mahindra (RBL Bank investment)
and Maruti Suzuki (Gujarat plant valuation) are a challenge. We reiterate our
REDUCE rating on Tata Motors and TVS Motor, as global operation challenges
overrule domestic recovery benefit at their current rich valuations.
27
India
Strategy Note │ August 26, 2023
Banking/NBFC sectors
• 1QFY24 results review: 1QFY24 witnessed credit growth easing, which was
on expected lines amid credit saturation due to overleveraging as well as
slowing consumption demand. However, the sporadicity in retail demand is
more interesting as a few lenders are growing faster compared to others,
grabbing market share. State Bank of India, HDFC Bank & ICICI Bank have
done well on the retail lending side while Axis Bank’s struggle over retail loans
(especially mortgages) is clearly visible. Our expectation of NBFCs
outperforming banks on the growth front due to deeper market penetration and
faster turnaround time is also playing out well. Corporate credit for most lenders
was sluggish during the quarter, with no major signs of the private capex cycle
commencing. We continue to remain skeptical of corporate demand due to a
variety of borrowing instruments (apart from bank borrowings) available to
them.
• Margin pressure visible across lenders: This trend is likely to continue. Most
banks and NBFCs have reported margin compression during the quarter amid
a rise in the cost of borrowing (mainly deposits in the case of banks) as well as
higher liquidity on the balance sheet (mainly for NBFCs). SBI &
Cholamandalam Investment and Finance Corporation were the worst-hit
during the quarter whereas HDFC Bank and IndusInd Bank performed better.
We continue to believe that banks are more vulnerable on the margin front as
repricing of low-cost deposits may continue whereas with an elevated share of
28
India
Strategy Note │ August 26, 2023
variable rate lending book, which is linked to the external benchmark rates
(mainly repo), any further rise in yields is capped due to stagnant policy rates.
We expect margin compression to remain for a while but for NBFCs, repricing
the loan book at higher rates and a cap over the cost of borrowings will ensure
a better margin profile.
• Elevated opex amid higher employee attrition & branch expansion: We
have seen a sharp surge in operating expenses for most lenders, but Axis Bank
and IndusInd Bank were the worst-hit. A higher level of employee attrition is
keeping employee costs higher and geographic expansion (branch addition) is
keeping the overall operating expenses relatively elevated, resulting in
deterioration of the cost-to-income ratio. However, the phenomena will improve
over the coming quarters as the branches achieve break-even.
• Asset quality stable but we prefer to stay cautious: The asset quality trend
in 1QFY24 remained flat sequentially with a steady headline non-performing
asset or NPA ratio across banks and NBFCs. However, there has been a surge
in credit costs, visible specifically in the case of Axis Bank and SBI Cards. We
prefer to remain cautious, especially on SME/MSME loans (including loan
against property or LAP loans) in semi-urban and rural India, due to
overleveraging amid oversupply of funds.
• We prefer HDFC Bank, SBI, MMFS, Bajaj Finance and Spandana: HDFC
Bank (ADD, Rs2,000) is our preferred pick among banks due to its expanded
reach and a superior liability profile. We also like SBI (ADD, Rs800) for its
superior market penetration-led growth. Among NBFCs, we continue to like
MMFS (ADD, Rs430) and Spandana Sphoorty (ADD, Rs1,000) amid visible
turnaround and improving return ratios. We also prefer Bajaj Finance (ADD,
Rs9,000) due to its ability to manage profitable growth. We continue to like
Cholamandalam Finance (ADD, Rs1,350) due to its aggressive growth, but we
see a limited upside due to probable equity dilution risk.
29
India
Strategy Note │ August 26, 2023
Cement sector
• In 1QFY24, our analysis of top-15 listed cement companies shows that overall
volume improvement for the industry was very strong (1Q volume grew by
~16% yoy). In our coverage universe, TRCL, JKCE, UTCEM, and SRCM
posted industry-leading growth, largely driven by ramp-up in their respective
new capacity. Industry demand prospects continue to remain positive (barring
seasonality impact so far in 2Q), considering strong traction in government
projects, primarily led by general elections in 2024. Many producers expect
double-digit demand growth for the industry in FY24F and strong growth for
themselves, though some weakness is seen during the monsoon season.
• However, unit EBITDA improvement has been subdued due to weak-to-flattish
realization and a gradual decline in power and fuel costs during the quarter.
The industry has witnessed an average only Rs55/t input cost savings on a
qoq basis in 1Q. Despite the recent uptick in pet-coke prices (US$15-20/t in
the last one month), we expect the industry to report Rs180-220/t input cost
savings in the next couple of quarters (mostly from 3QFY24F), which would aid
EBITDA/t recovery in 2HFY24F.
• Pricing: As per our channel check, dealers are surprised by price hikes, given
the subdued volume so far in 2Q; hence, we doubt the sustainability of such
price hikes. Management commentaries highlighted stable prices so far in 2Q.
However, there is a possibility that prices may increase in Sep 2023F, which
generally do, and fuel prices have seen some increase in recent days which is
exerting pressure on the producers to increase product prices.
• Capacity expansion: Most capacity expansion projects are progressing as per
schedule. During 1Q, new capacity addition announcements were made by
UTCEM and SRCM. ACEM announced the acquisition of Sanghi Cement and
its medium-term target of achieving 101mtpa capacity by FY26F, and also
reiterated its 140mtpa target for FY28F.
• Consolidation will remain high in the medium-long term. We feel the top 4-5
players will grow faster than the market at the cost of small and regional
players. We believe this trend will continue, given the ability of large players to
service the market from multiple locations, and we expect smaller incompetent
players to exit the space for some larger players. A few large players’ recent
commentaries highlighted that capital allocation and deal valuations will be key
factors that will be considered while acquiring any assets.
• With the benefit of low-cost fuel inventory and better volume, we believe the
margins will continue to improve despite muted cement prices. We retain our
Overweight stance on the sector from a medium- to long-term perspective, with
UTCEM, Adani Cement, DALBHARA and BCORP as our top stock picks.
30
India
Strategy Note │ August 26, 2023
Chemical sector
• Chemical companies disappointed in 1QFY24 as their margins were under
pressure, and the future of most Indian chemical majors will be driven by three
factors: 1) Crude oil prices, which drive the prices of most raw materials for
Indian chemical companies. 2) The global channel destocking in
agrochemicals and electric vehicle chemicals. 3) The regulatory changes
around the world, particularly for fluoropolymers and refrigerants. We don’t
believe that it’s the right time to do bottom fishing in the sector because the
bottom is still far away.
• The surge in crude oil prices will have a passing impact on naphtha. Naphtha
is the main raw material for key components such as ethylene, propylene,
benzene and multiple other petrochemicals. Ethylene spreads over naphtha
have touched a historic low, mirroring the trend in propylene, which also
witnesses a price hike due to rising cost of naphtha. A mean reversion in
propylene spreads over naphtha is on the cards which, coupled with the rise in
crude oil prices, can exert pressure on the raw material side. Currently,
chemicals are facing demand problems and raw material inflation is likely to
follow in the coming quarters.
• We like Camlin Fine Sciences in our chemical coverage universe, but we
maintain a REDUCE rating on Clean Science and Technology, Gujarat
Flourochemicals, and SRF.
Defence sector
• Financial performance: Defence companies’ sales in 1QFY24 were a mixed
bag – Bharat Electronics (BEL) reported strong sales, Hindustan Aeronautics
(HAL) marginally missed our estimates, and Bharat Dynamics or BDL’s sales
declined 57% yoy and missed estimates by 63% due to continued supply chain
problems. A higher cash balance at the end of FY23 resulted in higher interest
income, which boosted PAT for all companies.
31
India
Strategy Note │ August 26, 2023
• Order book: The order book for companies continues to remain strong. BEL
has a healthy order book of Rs654bn (3.7x TTM sales). Going ahead, BEL
expects robust order booking of more than Rs200bn in FY24F. The order
backlog for BDL stands at Rs202bn (8.2x FY23 sales). HAL has an order book
of over Rs800bn (3x TTM sales) at the end of FY23, and a further order pipeline
of Rs480bn for FY24F.
• Guidance: HAL has given revenue growth guidance of 10-12% for FY24F/25F
with the EBITDA margin expected to improve by 100bp yoy. BEL projects a
topline growth of ~17% for FY24F and the EBITDA margin in the range of 23%-
24% for FY24F. BDL has given revenue growth guidance of~30% with the
EBITDA margin at 20%-23% for FY24F.
• While defence companies’ numbers are volatile on a quarterly basis, 1Q is
usually a tepid quarter for execution and order finalization for these companies.
Hence, a strong order pipeline and the government’s focus on indigenization
and export growth, in our view, bode well for defence companies.
• Our view: Post sharp run-up in the public sector defence share prices in the
last six months, we remain cautiously optimistic, retaining our Overweight
stance and maintaining ADD rating on BEL, BDL and HAL.
Diagnostics sector
• Dr. Lal Pathlabs beat our estimates while Metropolis Healthcare and Thyrocare
reported lower-than-estimated financial performance in 1QFY24.
• Non-Covid patient volume growth stayed soft while sample volume growth was
relatively higher. Post-Covid, the number of tests per patient has been rising
consistently. Realization per patient improved marginally for all diagnostic labs
under our coverage on the back of price hikes taken on a few specialized tests,
better test mix and a higher share of sale of wellness packages.
• The pace of entry of new players in the segment slowed down considerably.
Online-only labs reduced discount rates meaningfully over the past six months.
In fact, revenue from partnerships with online aggregators declined qoq for
Thyrocare, implying a material slowdown in their business run-rate.
• Large acquisitions done so far have not yielded the expected results and
integration benefits are expected to aid growth/margins over the next 12
months.
• Going ahead, recovery in patient volume back to pre-Covid levels, higher
revenue growth rate in new markets and acquired labs, M&A cost synergies
and competitive intensity are key parameters to monitor.
• We upgraded Metropolis Healthcare to an ADD rating and downgraded
Thyrocare to a HOLD. Retained our HOLD rating on Dr. Lal Pathlabs.
• Top picks: Dr. Lal Pathlabs and Metropolis Healthcare.
32
India
Strategy Note │ August 26, 2023
33
India
Strategy Note │ August 26, 2023
34
India
Strategy Note │ August 26, 2023
Pharma sector
• Strong 1QFY24 performance: The quarterly earnings were a litmus test for
the sector, especially after the sharp outperformance since the start of this
financial year. To this end, most companies fared better than expectations, with
nearly 55% of our coverage universe posting a strong beat, surprising
positively both on the US market growth and margins, and another 20%
reporting an in-line set of numbers. The commentary was upbeat as well, with
most companies giving guidance of a stable-to-improving US business
trajectory and expecting the margins to sustain/improve. India business
performance was relatively mixed - larger names like Sun Pharma and Alkem
Laboratories showed weak growth, while others outperformed. API companies
disappointed on the earnings front (Divi’s Laboratories, Laurus Labs) but gave
guidance of an improvement going ahead.
• US market outlook remains strong: Most companies alluded to a stable
pricing environment in the US market, with selective opportunities from product
shortage and lesser erosion in the base business. Aurobindo Phama gave
guidance of US$500m+ revenue in Eugia (vs. US$411m in FY23) while Zydus
Lifesciences gave guidance of a double-digit growth in US revenue despite
assuming competition in gAsacol HD. gRevlimid remains an important driver
of US growth, and while 1Q contribution was much higher than expectations
(specifically for Dr. Reddy’s Laboratories, Sun Pharma and Zydus
Lifesciences), the product is likely to be erratic in terms of contribution going
ahead.
• Sanguine margin outlook in the medium term: On an average, gross margin
improved by 260bp QoQ for the sector and the EBITDA margin improved by
297bp QoQ in 1Q. Softening raw material prices, depletion of high-cost raw
material inventory, higher gRevlimid sales, reduction in logistic costs and
operating leverage played out in favour. Aurobindo Pharma (from 17% to 18%+
and 20%+ including gRevlimid from Oct 2023F) and Zydus Lifesciences (150-
200bp margin expansion vs. 50-100bp earlier) upgraded their FY24F margin
guidance. Post 1Q earnings, investor confidence in Ajanta Pharma’s margin
guidance of 25%+ was also high.
• Remain selective: In our last report, we had highlighted margin expansion to
continue driving the sector’s outperformance, and 1Q earnings/outlook largely
validates that. However, after the sharp run-up and thus high valuations, we
prefer to remain selective. Aurobindo Pharma, Torrent Pharma and Ajanta
Pharma are our top stock picks.
35
India
Strategy Note │ August 26, 2023
DISCLAIMER
This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research
Services Private Ltd.(formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as “IRSPL”). IRSPL is registered with
SEBI as a Research Analyst vide Registration No. INH000007793. Pursuant to a trademark agreement, IRSPL has adopted “Incred Equities” as its
trademark for use in this report.
The term “IRSPL” shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not
directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication,
availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing
requirements within such jurisdictions.
This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated,
stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any
purpose without the prior written consent of IRSPL.
The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.
IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity
of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this
report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant;
(ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy,
completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their
respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including
but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.
Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market
data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market.
Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information
disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is
made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other
subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are
contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of
future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose
more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any
person to buy or sell any investments.
The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other non-
confidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of
interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their
duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among
other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request.
The report is not a “prospectus” as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or
registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India.
No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or
intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.
The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other
activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.
The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other
activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.
IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different
conclusion from the information presented in this report.
Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report
36
India
Strategy Note │ August 26, 2023
Analyst/ Entity/
Relative Associates
any financial interests in the company covered in this report (subject company) and nature of such financial
NO NO
interest
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month
immediately preceding the date of publication of the research report NO NO
or date of the public appearance;
any other material conflict of interest at the time of publication of the research report
NO NO
or at the time of public appearance
received any compensation from the subject company in the past twelve months
for investment banking or merchant banking or brokerage services or investment advisory or depository or
distribution from the subject company in the last twelve months for products/services other than investment NO NO
banking or merchant banking or broker- age services or investment advisory or depository or distribution from
the subject company in the last twelve months
managed or co-managed public offering of securities for the subject company in the last twelve months NO NO
received any compensation or other benefits from the subject company or third party in connection with the
NO NO
research report
served as an officer, director or employee of the subject company NO NO
been engaged in market making activity for the subject company NO NO
Analyst declaration
• The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his
or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and
autonomously in an unbiased manner.
• No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or
view(s) in this report or based any specific investment banking transaction.
• The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
• The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
• The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm
performance, client feedback and competitive factors.
IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any
securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.
IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and
may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an
underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d)
may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies)
and/or (e) solicit such investment, advisory or other services from any entity mentioned in thisreport and/or (f) act as a lender/borrower to such
company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities
(physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or
in the result of which they play a key part.
37